Acousia Therapeutics GmbH, a clinical stage biotech company located in Tübingen, Germany, will be presenting their latest clinical study at two upcoming conferences in August and September of 2024. The ACOU085 Phase 2 PROHEAR study will be discussed at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston, Massachusetts from August 20-22, and at the 36th World Congress of Audiology in Paris, France from September 19-22.
The PROHEAR study, endorsed by the Study Group of the German Society of Otorhinolaryngology, is a placebo-controlled Phase 2a study investigating the effectiveness of ACOU085 in protecting the hearing of patients with testicular cancer undergoing high-dose chemotherapy. The study is being conducted at major university clinics in Germany under the approval of the German Federal Institute for Drugs and Medical Devices and the European Medicines Agency.
Dr. Jonas Dyhrfjeld-Johnsen, CDO and Managing Director of Acousia Therapeutics, will be presenting the Phase 2 PROHEAR study at the HansonWade Inner Ear Disorders Therapeutics Summit on August 21. He will also be participating in roundtable and panel discussions and serving as a chair for the summit. On September 22, Dr. Dyhrfjeld-Johnsen will present the study to an international audience at the 36th World Congress of Audiology in Paris.
“We are honored to have the opportunity to present our ongoing PROHEAR study to the international clinical community and our industry peers,” said Dr. Dyhrfjeld-Johnsen. “The interest in our study is a testament to the pressing need for effective treatments for hearing loss, particularly in patients undergoing life-saving chemotherapy.”
ACOU085 (INN: Bimokalner) is a first-in-class drug candidate that is delivered using standard transtympanic administration of a proprietary slow-release gel formulation. It targets ototoxic hearing loss, a common and severe side effect of cisplatin chemotherapy that causes irreversible damage to the sensory cells in the inner ear. ACOU085 has shown promising results in preclinical models in reducing cisplatin-induced hearing loss and preserving outer hair cells.
For more information about the study and Acousia Therapeutics, please contact Dr. Tim Boelke at boelke@acousia.com or visit www.acousia.com. This press release is distributed by Pressat.co.uk.
